Josep Mallolas-Masferrer
Elite in HIV/AIDS

Josep Mallolas-Masferrer

Villarroel Street 170, 
Barcelona, CT, ES 
Elite in HIV/AIDS
Villarroel Street 170, 
Barcelona, CT, ES 
OverviewLocationsClinical Research

Overview

Josep Mallolas-Masferrer practices in Barcelona, Spain. Mr. Mallolas-Masferrer is rated as an Elite expert by MediFind in the treatment of HIV/AIDS. His top areas of expertise are HIV/AIDS, Hepatitis, Hepatitis C, and Febrile Neutropenia.

His clinical research consists of co-authoring 119 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 70 articles and participated in 1 clinical trial in the study of HIV/AIDS.

Gender
Male

Locations

Villarroel Street 170, Barcelona, CT 08036, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

An Open-Label, Multi-Centre, Randomised Study to Investigate Integrase Inhibitor Versus Boosted Protease Inhibitor Antiretroviral Therapy for Patients With Advanced HIV Disease
An Open-Label, Multi-Centre, Randomised Study to Investigate Integrase Inhibitor Versus Boosted Protease Inhibitor Antiretroviral Therapy for Patients With Advanced HIV Disease
Enrollment Status: Completed
Publish Date: December 17, 2025
Intervention Type: Drug
Study Drugs: Biktarvy, Symtuza
Study Phase: Phase 3
A Phase IIb, Randomized, Double-blind, Parallel-group Study to Assess the Efficacy, Safety, Tolerability, and Resistance Profile of GSK3640254 in Combination With Dolutegravir Compared to Dolutegravir Plus Lamivudine in HIV-1 Infected, Treatment-naïve Adults
A Phase IIb, Randomized, Double-blind, Parallel-group Study to Assess the Efficacy, Safety, Tolerability, and Resistance Profile of GSK3640254 in Combination With Dolutegravir Compared to Dolutegravir Plus Lamivudine in HIV-1 Infected, Treatment-naïve Adults
Enrollment Status: Terminated
Publish Date: December 14, 2023
Intervention Type: Drug
Study Drugs: GSK3640254, Dolutegravir, Lamivudine
Study Phase: Phase 2
View 1 Less Clinical Trial

119 Total Publications

Incidence, Clinical Features and Vaccination Coverage of Pneumococcal Disease in People Living with HIV: A Retrospective Cohort Study (2015-2024).
Incidence, Clinical Features and Vaccination Coverage of Pneumococcal Disease in People Living with HIV: A Retrospective Cohort Study (2015-2024).
Journal: Vaccines
Published: October 31, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Mallolas-Masferrer's expertise for a condition
ConditionClose
    View All 14 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile